Skip to main content
Erschienen in: Surgical Endoscopy 6/2010

01.06.2010

Increased mRNA expression of epidermal growth factor receptor, human epidermal receptor, and survivin in human gastric cancer after the surgical stress of laparotomy versus carbon dioxide pneumoperitoneum in a murine model

verfasst von: Anwar Tawfik Amin, Norio Shiraishi, Shigeo Ninomiya, Masaaki Tajima, Masafumi Inomata, Seigo Kitano

Erschienen in: Surgical Endoscopy | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Surgical impact may be associated with enhanced tumor growth and chemoresistance. This study aimed to evaluate the effect of surgical impact on the mRNA expression of survivin, epidermal growth factor receptor (EGFR), and human epidermal receptor (HER2) in tumors after pneumoperitoneum versus laparotomy.

Methods

Nude mice were inoculated intraperitoneally with human gastric cancer cells (MKN45). Then laparotomy, carbon dioxide (CO2) pneumoperitoneum, and anesthesia alone were performed randomly, after which EGFR, HER2, and survivin mRNA expression using reverse transcription-polymerase chain reaction (RT-PCR) was evaluated.

Results

The expression of EGFR and HER2 mRNA increased significantly after the experiment. However, it was higher after laparotomy than after CO2 pneumoperitoneum at almost all examined time points. Survivin mRNA expression increased significantly in the first 48 h, then returned to the control level. It was higher after laparotomy than after CO2 pneumoperitoneum 48 h after the surgical procedures.

Conclusion

The expression of EGFR, HER2, and survivin increased after each surgical procedure. However it was lower after CO2 pneumoperitoneum than after laparotomy. This might be associated with changes in the chemosensitivity of the remnant cancer cells after surgery, supporting the use of minimally invasive surgery for cancer.
Literatur
1.
Zurück zum Zitat Yu W, Whang I, Suh I, Averbach A, Chang D, Sugarbaker PH (1998) Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 228:347–354CrossRefPubMed Yu W, Whang I, Suh I, Averbach A, Chang D, Sugarbaker PH (1998) Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 228:347–354CrossRefPubMed
2.
Zurück zum Zitat Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY (2009) Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 100:298–304CrossRefPubMed Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY (2009) Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 100:298–304CrossRefPubMed
3.
Zurück zum Zitat Asanuma H, Torigoe T, Kamiguchi K, Hirohashi Y, Ohmura T, Hirata K, Sato M, Sato N (2005) Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res 65:11018–11025CrossRefPubMed Asanuma H, Torigoe T, Kamiguchi K, Hirohashi Y, Ohmura T, Hirata K, Sato M, Sato N (2005) Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res 65:11018–11025CrossRefPubMed
4.
Zurück zum Zitat Jonker DJ, O’Callaghan CJ, Karapetis Cs, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, vanHazel G, Wiezbicki R, Langer C, Moore MJ (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040–2048CrossRefPubMed Jonker DJ, O’Callaghan CJ, Karapetis Cs, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, vanHazel G, Wiezbicki R, Langer C, Moore MJ (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040–2048CrossRefPubMed
5.
Zurück zum Zitat Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C, Mutri V, Gianetta L, Giaquinta S, Funaioli C, Berardi R, Longobardi C, Piana E, Martoni AA (2007) Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FULCETUX study). Ann Oncol 18:510–517CrossRefPubMed Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C, Mutri V, Gianetta L, Giaquinta S, Funaioli C, Berardi R, Longobardi C, Piana E, Martoni AA (2007) Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FULCETUX study). Ann Oncol 18:510–517CrossRefPubMed
6.
Zurück zum Zitat Coffey JC, Wang JH, Smith MJ, Laing A, Bouchier-Hayes D, Cotter TG, Redmond HP (2005) Phosphoinositide 3-kinase accelerates postoperative tumor growth by inhibiting apoptosis and enhancing resistance to chemotherapy-induced apoptosis. J Biol Chem 280:20968–20977CrossRefPubMed Coffey JC, Wang JH, Smith MJ, Laing A, Bouchier-Hayes D, Cotter TG, Redmond HP (2005) Phosphoinositide 3-kinase accelerates postoperative tumor growth by inhibiting apoptosis and enhancing resistance to chemotherapy-induced apoptosis. J Biol Chem 280:20968–20977CrossRefPubMed
7.
Zurück zum Zitat Lee SW, Gleason N, Blanco I, Asi ZK, Whelan RL (2002) Higher colon cancer tumor proliferative index and lower tumor cell death rate in mice undergoing laparotomy vs insufflation. Surg Endosc 16:36–39CrossRefPubMed Lee SW, Gleason N, Blanco I, Asi ZK, Whelan RL (2002) Higher colon cancer tumor proliferative index and lower tumor cell death rate in mice undergoing laparotomy vs insufflation. Surg Endosc 16:36–39CrossRefPubMed
8.
Zurück zum Zitat Qadri SS, Wang JH, Coffey JC, Alam M, O’Donnell A, Aherne T, Redmond HP (2005) Surgically induced accelerated local and distant tumor growth is significantly attenuated by selective COX-2 inhibition. Ann Thorac Surg 79:990–995CrossRefPubMed Qadri SS, Wang JH, Coffey JC, Alam M, O’Donnell A, Aherne T, Redmond HP (2005) Surgically induced accelerated local and distant tumor growth is significantly attenuated by selective COX-2 inhibition. Ann Thorac Surg 79:990–995CrossRefPubMed
9.
Zurück zum Zitat Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T (1986) The product of the human c-erbB-2 gene: a 185-kilo Dalton glycoprotein with tyrosine kinase activity. Science 232:1644–1646CrossRefPubMed Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T (1986) The product of the human c-erbB-2 gene: a 185-kilo Dalton glycoprotein with tyrosine kinase activity. Science 232:1644–1646CrossRefPubMed
10.
Zurück zum Zitat Gravalos C, Jimeno A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19:1523–1529CrossRefPubMed Gravalos C, Jimeno A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19:1523–1529CrossRefPubMed
11.
Zurück zum Zitat Altieri DC (2003) Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3:46–54CrossRefPubMed Altieri DC (2003) Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3:46–54CrossRefPubMed
12.
Zurück zum Zitat Longlley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205:275–292CrossRef Longlley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205:275–292CrossRef
13.
Zurück zum Zitat Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, Chung CW, Jung YK, Oh BH (2001) An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40:1117–1123CrossRefPubMed Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, Chung CW, Jung YK, Oh BH (2001) An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40:1117–1123CrossRefPubMed
14.
Zurück zum Zitat Wang Q, Greene MI (2005) EGFR enhances survivin expression through the phosphoinositide 3 (IP-3) kinase signaling pathway. Exp Mol Bathol 79:100–107CrossRef Wang Q, Greene MI (2005) EGFR enhances survivin expression through the phosphoinositide 3 (IP-3) kinase signaling pathway. Exp Mol Bathol 79:100–107CrossRef
15.
Zurück zum Zitat Qiu L, Wang Q, Di W, Jiang Q, Schefeller E, Derby S, Wanebo H, Yan B, Wan Y (2005) Transient activation of EGFR/AKT pathway and expression of survivin contribute to reduced sensitivity of human melanoma cells to betulinic acid. Int J Oncol 27:823–830PubMed Qiu L, Wang Q, Di W, Jiang Q, Schefeller E, Derby S, Wanebo H, Yan B, Wan Y (2005) Transient activation of EGFR/AKT pathway and expression of survivin contribute to reduced sensitivity of human melanoma cells to betulinic acid. Int J Oncol 27:823–830PubMed
16.
Zurück zum Zitat Peng XH, Cao ZH, Xia JT, Carlson GW, Lewis MM, Wood WC, Yang L (2005) Real-time detection of gene expression in cancer cells using molecular beacon imaging: new strategies for cancer research. Cancer Res 65:1909–1917CrossRefPubMed Peng XH, Cao ZH, Xia JT, Carlson GW, Lewis MM, Wood WC, Yang L (2005) Real-time detection of gene expression in cancer cells using molecular beacon imaging: new strategies for cancer research. Cancer Res 65:1909–1917CrossRefPubMed
17.
Zurück zum Zitat Ikeguchi M, Liu J, Kaibara N (2002) Expression of survivin mRNA and protein in gastric cancer cell line (MKN45) during cisplatin treatment. Apoptosis 7:23–29CrossRefPubMed Ikeguchi M, Liu J, Kaibara N (2002) Expression of survivin mRNA and protein in gastric cancer cell line (MKN45) during cisplatin treatment. Apoptosis 7:23–29CrossRefPubMed
18.
Zurück zum Zitat Nakamura M, Tsuji N, Asanuma K, Kobayashi D, Yagihashi A, Hirata K, Torigoe T, Sato N, Watanabe N (2004) Survivin as a predictor of cis-diammine dichloroplatinum sensitivity in gastric cancer patients. Cancer Sci 95:44–51CrossRefPubMed Nakamura M, Tsuji N, Asanuma K, Kobayashi D, Yagihashi A, Hirata K, Torigoe T, Sato N, Watanabe N (2004) Survivin as a predictor of cis-diammine dichloroplatinum sensitivity in gastric cancer patients. Cancer Sci 95:44–51CrossRefPubMed
19.
Zurück zum Zitat Peng XH, Karna P, Cao Z, Jiang BH, Zhou M, Yang L (2006) Cross-talk between epidermal growth factor receptor and hypoxia inducible factor-1α signal pathways increase resistance to apoptosis by upregulating survivin gene expression. J Biol Chem 281:25903–25914CrossRefPubMed Peng XH, Karna P, Cao Z, Jiang BH, Zhou M, Yang L (2006) Cross-talk between epidermal growth factor receptor and hypoxia inducible factor-1α signal pathways increase resistance to apoptosis by upregulating survivin gene expression. J Biol Chem 281:25903–25914CrossRefPubMed
20.
Zurück zum Zitat Matsui Y, Inomata M, Tojigamori M, Sonoda K, Shiraishi N, Kitano S (2005) Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti HER2 antobody in a murine model. Int J Oncol 27:681–685PubMed Matsui Y, Inomata M, Tojigamori M, Sonoda K, Shiraishi N, Kitano S (2005) Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti HER2 antobody in a murine model. Int J Oncol 27:681–685PubMed
21.
Zurück zum Zitat Suematsu T, Shiromizu A, Yamaguchi K, Shiraishi N, Adachi Y, Kitano S (1999) Convenient murine pneumoperitoneal model for the study of laparoscopic cancer surgery. Surg Laparo Endo Per 9:279–281CrossRef Suematsu T, Shiromizu A, Yamaguchi K, Shiraishi N, Adachi Y, Kitano S (1999) Convenient murine pneumoperitoneal model for the study of laparoscopic cancer surgery. Surg Laparo Endo Per 9:279–281CrossRef
22.
Zurück zum Zitat Narita T, Taga T, Sugita K, Nakazawa S, Ohta S (2001) The autocrine loop of epidermal growth factor receptor–epidermal growth factor/transforming factor alpha in malignant rhabdoid tumor cell lines: heterogeneity of autocrine mechanism in TTC 549. Jpn J Cancer Res 92:269–278PubMed Narita T, Taga T, Sugita K, Nakazawa S, Ohta S (2001) The autocrine loop of epidermal growth factor receptor–epidermal growth factor/transforming factor alpha in malignant rhabdoid tumor cell lines: heterogeneity of autocrine mechanism in TTC 549. Jpn J Cancer Res 92:269–278PubMed
23.
Zurück zum Zitat Revillion F, Hornez L, Peyrat JP (1997) Quuatification of c-erbB-2 gene expression in breast cancer by competitive RT-PCR. Clin Chem 43:2114–2120PubMed Revillion F, Hornez L, Peyrat JP (1997) Quuatification of c-erbB-2 gene expression in breast cancer by competitive RT-PCR. Clin Chem 43:2114–2120PubMed
24.
Zurück zum Zitat Zhang T, Fields JZ, Ehrlich SM (2004) The chemopreventive agent sulindac attenuates expression of the antiapoptotic protein survivin in colorectal carcinoma cells. J Pharmacol Exp Ther 308:434–437CrossRefPubMed Zhang T, Fields JZ, Ehrlich SM (2004) The chemopreventive agent sulindac attenuates expression of the antiapoptotic protein survivin in colorectal carcinoma cells. J Pharmacol Exp Ther 308:434–437CrossRefPubMed
25.
Zurück zum Zitat Anwar TA, Shiraishi N, Ninomyia S, Tajima M, Inomata M, Kitano S (2009) Activation of nuclear factor kappa B (NFκB) and induction of migration inhibitory factor (MIF) in tumors by surgical stress of laparotomy vs CO2 pneumoperitoneum: an animal experiment. Surg Endosc. doi:10.1007/s00464-009-0609-x Anwar TA, Shiraishi N, Ninomyia S, Tajima M, Inomata M, Kitano S (2009) Activation of nuclear factor kappa B (NFκB) and induction of migration inhibitory factor (MIF) in tumors by surgical stress of laparotomy vs CO2 pneumoperitoneum: an animal experiment. Surg Endosc. doi:10.​1007/​s00464-009-0609-x
26.
Zurück zum Zitat Abramovitch R, Marikovsky M, Meir G, Neeman M (1999) Stimulation of tumor growth by wound-derived growth factors. Br J Cancer 79:1392–1398CrossRefPubMed Abramovitch R, Marikovsky M, Meir G, Neeman M (1999) Stimulation of tumor growth by wound-derived growth factors. Br J Cancer 79:1392–1398CrossRefPubMed
27.
Zurück zum Zitat Rupec RA, Baeuerle PA (1995) The genomic response of tumor cells to hypoxia and reoxygenation: differential activation of transcription factors AP-1 and NFκB. Eur J Biochem 234:632–640CrossRefPubMed Rupec RA, Baeuerle PA (1995) The genomic response of tumor cells to hypoxia and reoxygenation: differential activation of transcription factors AP-1 and NFκB. Eur J Biochem 234:632–640CrossRefPubMed
28.
Zurück zum Zitat Lundberg O, Kristoffersson A (2005) Reduction of abdominal wall blood flow by clamping or carbon dioxide insufflation increases tumor growth in the abdominal wall: an experimental study in rats. Surg Endosc 19:720–723CrossRefPubMed Lundberg O, Kristoffersson A (2005) Reduction of abdominal wall blood flow by clamping or carbon dioxide insufflation increases tumor growth in the abdominal wall: an experimental study in rats. Surg Endosc 19:720–723CrossRefPubMed
29.
Zurück zum Zitat Hsieh HL, Sun CC, Wu CB, Wu CY, Tung WH, Wang HH, Yang CM (2008) Sphnigosine 1-phosphate induces EGFR expression via Akt/NFκB and ERK/Ap-1 pathways in rat vascular smooth muscle cells. J Cell Biochem 103:1732–1746CrossRefPubMed Hsieh HL, Sun CC, Wu CB, Wu CY, Tung WH, Wang HH, Yang CM (2008) Sphnigosine 1-phosphate induces EGFR expression via Akt/NFκB and ERK/Ap-1 pathways in rat vascular smooth muscle cells. J Cell Biochem 103:1732–1746CrossRefPubMed
30.
Zurück zum Zitat Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E, Ohira M, Hashizume K, Kobayashi H, Kaneko Y, Nakagawara A (2000) High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19:617–623CrossRefPubMed Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E, Ohira M, Hashizume K, Kobayashi H, Kaneko Y, Nakagawara A (2000) High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19:617–623CrossRefPubMed
31.
Zurück zum Zitat Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N (1998) Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58:5071–5074PubMed Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N (1998) Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58:5071–5074PubMed
32.
Zurück zum Zitat Mayo SC, Austin DF, Sheppard BC, Mori M, Shipley DK, Billingsley KG (2009) Evolving preoperative evaluation of patients with pancreatic cancer: does laparoscopy have a role in the current era. J Am Coll Surg 208:87–95CrossRefPubMed Mayo SC, Austin DF, Sheppard BC, Mori M, Shipley DK, Billingsley KG (2009) Evolving preoperative evaluation of patients with pancreatic cancer: does laparoscopy have a role in the current era. J Am Coll Surg 208:87–95CrossRefPubMed
33.
Zurück zum Zitat Tagliabue E, Agresti R, Carcangiu ML, Ghirelli C, Morelli D, Campiglio M, Martel M, Giovanazzi R, Greco M, Balsari A, Menard S (2003) Role of HER2 in wound induced breast carcinoma proliferation. Lancet 362:527–533CrossRefPubMed Tagliabue E, Agresti R, Carcangiu ML, Ghirelli C, Morelli D, Campiglio M, Martel M, Giovanazzi R, Greco M, Balsari A, Menard S (2003) Role of HER2 in wound induced breast carcinoma proliferation. Lancet 362:527–533CrossRefPubMed
34.
Zurück zum Zitat Jarnagin WR, Delman K, Kooby D, Mastorides S, Zager J, Brennan MF, Blumgart LH, Federoff H, Fong Y (2000) Neoadjuvant interleukin-12 immunogene therapy protects against cancer recurrence after liver resection in an animal model. Ann Surg 231:762–771CrossRefPubMed Jarnagin WR, Delman K, Kooby D, Mastorides S, Zager J, Brennan MF, Blumgart LH, Federoff H, Fong Y (2000) Neoadjuvant interleukin-12 immunogene therapy protects against cancer recurrence after liver resection in an animal model. Ann Surg 231:762–771CrossRefPubMed
35.
Zurück zum Zitat Wei JM, Shiraishi N, Goto S, Yasuda K, Inomata M, Kitano S (2008) Laparoscopy-assisted distal gastrectomy with D1 + β compared with D1α lymph node dissection. Surg Endosc 22:955–960CrossRefPubMed Wei JM, Shiraishi N, Goto S, Yasuda K, Inomata M, Kitano S (2008) Laparoscopy-assisted distal gastrectomy with D1 + β compared with D1α lymph node dissection. Surg Endosc 22:955–960CrossRefPubMed
Metadaten
Titel
Increased mRNA expression of epidermal growth factor receptor, human epidermal receptor, and survivin in human gastric cancer after the surgical stress of laparotomy versus carbon dioxide pneumoperitoneum in a murine model
verfasst von
Anwar Tawfik Amin
Norio Shiraishi
Shigeo Ninomiya
Masaaki Tajima
Masafumi Inomata
Seigo Kitano
Publikationsdatum
01.06.2010
Verlag
Springer-Verlag
Erschienen in
Surgical Endoscopy / Ausgabe 6/2010
Print ISSN: 0930-2794
Elektronische ISSN: 1432-2218
DOI
https://doi.org/10.1007/s00464-009-0793-8

Weitere Artikel der Ausgabe 6/2010

Surgical Endoscopy 6/2010 Zur Ausgabe

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Recycling im OP – möglich, aber teuer

05.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO2-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Im OP der Zukunft läuft nichts mehr ohne Kollege Roboter

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.